FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “DermTech, Inc. Rises Amid Agreement with Blue Cross Blue Shield of Texas“
DermTech, Inc. (NASDAQ: DMTK) surged over 30% in premarket trading after entering into an agreement with Blue Cross Blue Shield of Texas
DermTech’s gene expression-based Pigmented Lesion Assay for the early detection of melanoma is now available as an in-network option for Blue Cross Blue Shield of Texas’ Blue Essential, Traditional Indemnity and PPO/POS membership.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
For more information, please visit: DermTech, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.